Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14203048 | 0.93 | SLC6A2 (0.83) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14229089 | 0.93 | SLC6A2 (0.83) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL5045865 | 0.92 | SLC6A2 (0.81) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL5038421 | 0.92 | SLC6A2 (0.81) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14203012 | 0.88 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL5428490 | 0.87 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL5046054 | 0.87 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL5046050 | 0.87 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14202975 | 0.85 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL8284213 | 0.85 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660065-A2 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005020976-A2 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |